Day By Day < Go back

Gallery - click on the images to view the larger version

What we aim to achieve

Starting from the premise that people who are defined as ‘clinically extremely vulnerable’ are extremely valuable citizens with skills, knowledge, experience and other qualities to offer, to co-produce with people solutions to help them maintain, and hopefully improve, their health and well-being in ways that suit them.

What we do

Hold in-depth conversations with a wide diversity of people about what they see as most important for their health and well-being. 

Develop and test ideas with people that address the key themes that they have identified, and then co-produce innovative solutions with them.

You can find the project report here. Please contact us for a copy of the full report. 

Where we operate


Who is eligible

People who are defined as ‘clinically extremely vulnerable’. They include:

  • people who received solid organ transplants
  • people with specific cancers:
    • people with cancer who are undergoing active chemotherapy
    • people with lung cancer who are undergoing radical radiotherapy
    • people with cancers of the blood or bone marrow such as leukaemia, lymphoma or myeloma who are at any stage of treatment
    • people having immunotherapy or other continuing antibody treatments for cancer
    • people having other targeted cancer treatments that can affect the immune system, such as protein kinase inhibitors or PARP inhibitors
    • people who have had bone marrow or stem cell transplants in the last 6 months or who are still taking immunosuppression drugs
  • people with severe respiratory conditions including all cystic fibrosis, severe asthma and severe chronic obstructive pulmonary disease (COPD)
  • people with rare diseases that significantly increase the risk of infections (such as severe combined immunodeficiency (SCID), homozygous sickle cell)
  • people on immunosuppression therapies sufficient to significantly increase risk of infection
  • women who are pregnant with significant heart disease, congenital or acquired
  • other people who have also been classed as ‘clinically extremely vulnerable’, based on clinical judgement and an assessment of their needs

Who to Contact

Chris Dabbs (Chief Executive)

Contact details below

Who invests in us